Results · Apr-Jun 2026 · filed 14 Aug 2026
Alkem Laboratories Q1 FY27 results
Sales grew 11% to ₹3,740 crore from ₹3,371 crore in Apr-Jun 2025.
Operating profit grew 4% to ₹766 crore, an operating margin of 20.5% (down 1.4 points from a year ago).
Net profit fell 22% to ₹521 crore from ₹668 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +4%, net profit +107%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 3,740 | 3,371 | +11% |
| Operating profit (EBITDA) | 766.1 | 739.0 | +4% |
| Operating margin | 20.5% | 21.9% | −1.4 pts |
| Net profit | 521.0 | 667.9 | −22% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Alkem reported Apr–Jun 2026 revenue of ₹3,740 crore with 11% growth from a year earlier. India sales grew 10.3% while international grew 16%. EBITDA margin was 20.5%, but net profit fell 21.7% due to taxation. The company outperformed the Indian pharma market by 100 basis points.
The last 7 quarters
Filings that week
- 20 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 20 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 17 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting
- 15 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 14 Aug 2026Closure of Trading Window
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 14 Aug 2026Announcement Under Reg 30 (LODR)
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.